Abstract
Infectious peritonitis continues to be the leading cause of morbidity in patients on continuous ambulatory peritoneal dialysis (CAPD). Optimum management of CAPD-associated peritonitis requires a concerted effort toward the establishment of the specific agent causing the episode. We have reviewed the current literature relating to the diagnosis and institution of antimicrobial therapy. Controlled comparative trials are needed to determine the efficacy of potentially less toxic therapeutic regimens for peritonitis, for definition of and treatment of exit-site infections, and timing of catheter replacement.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
